Phase 4
N=85
Perineural Steroids for Peripheral Nerve Blocks
Osteoarthritis, Knee
Bottom Line
View on ClinicalTrials.gov: NCT02462148 ↗Enrolled (actual)
85
Serious AEs
0.0%
Results posted
Aug 2018
Primary outcome: Primary: Duration of Sensory Nerve Block — 37.00; 31.75; 29.67 hours
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Dexamethasone (Drug); Bupivacaine (Drug); Epinephrine (Drug); Saphenous Peripheral Nerve Block (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Wake Forest University Health Sciences
- Primary completion
- Aug 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Duration of Sensory Nerve Block |
37.00; 31.75; 29.67 | — |
| SECONDARY Verbal Pain Scores |
2.1; 2.3; 2.1; 0.8; 1.3; 1.1 | — |
| SECONDARY Rate of Post Operative Nausea and Vomiting |
5; 14; 4 | — |
| SECONDARY Neurologic Complications |
0; 0; 0 | — |
| SECONDARY Post Operative Opioid Use and Consumption |
27.16; 26.04; 42.33 | — |
| SECONDARY Time to First Opioid Analgesic Request |
686.18; 654.97; 658.17 | — |
Summary
This study will look at the efficacy of dexamethasone for prolongation of peripheral nerve blocks.
Eligibility Criteria
Inclusion Criteria
- elective robotic medial MAKO partial knee arthroplasty
- agreed to a regional anesthesia technique
Exclusion Criteria
- contraindications to regional anesthesia
- presence of a progressive neurological deficit
- a pre-existing coagulopathy, infection
- insulin and non-insulin dependent diabetes mellitus
- systemic use of corticosteroids within 30 days of surgery
- chronic use of an opioid analgesic (>3 months or a combined total of more than 40 mg Oxycodone equivalents a day)
- pregnancy
- a prior history of an adverse event (for example: psychosis) or an allergy to dexamethasone
Data sourced from ClinicalTrials.gov (NCT02462148). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.